Aggregate Upfront And Milestones Received

No definition available.

Name:	mdvn_AggregateUpfrontAndMilestonesReceived
Namespace Prefix:	mdvn_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Co-promotion of sales and medical affairs percentage.

+ References

No definition available.

+ Details

Name:	mdvn_CoPromotionOfSalesAndMedicalAffairsPercentage
Namespace Prefix:	mdvn_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Maximum Eligible Future Development Milestone Payments Under Collaboration Arrangement

+ References

No definition available.

+ Details

Name:	mdvn_MaximumEligibleFutureDevelopmentMilestonePaymentsUnderCollaborationArrangement
Namespace Prefix:	mdvn_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Maximum Eligible Future Sales Milestone Payments Under Collaboration Arrangement

+ References

No definition available.

+ Details

Name:	mdvn_MaximumEligibleFutureSalesMilestonePaymentsUnderCollaborationArrangement
Namespace Prefix:	mdvn_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Milestone Payments Received To Date Under Collaboration Arrangement

+ References

No definition available.

+ Details

Name:	mdvn_MilestonePaymentsReceivedToDateUnderCollaborationArrangement
Namespace Prefix:	mdvn_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Percentage of Development Milestone Payments To Licensor

+ References

No definition available.

+ Details

Name:	mdvn_PercentageOfDevelopmentMilestonePaymentsToLicensor
Namespace Prefix:	mdvn_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Percentage Of Net Sales Under Collaboration Agreement

+ References

No definition available.

+ Details

Name:	mdvn_PercentageOfNetSalesUnderCollaborationAgreement
Namespace Prefix:	mdvn_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Percentage of sales milestone payments.

+ References

No definition available.

+ Details

Name:	mdvn_PercentageOfSalesMilestonePayments
Namespace Prefix:	mdvn_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Remaining Eligible Future Milestone Payments Under Collaboration Arrangement

+ References

No definition available.

+ Details

Name:	mdvn_RemainingEligibleFutureMilestonePaymentsUnderCollaborationArrangement
Namespace Prefix:	mdvn_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Royalty Received On Ex Us Sales Per Collaboration Arrangement

+ References

No definition available.

+ Details

Name:	mdvn_RoyaltyReceivedOnExUsSalesPerCollaborationArrangement
Namespace Prefix:	mdvn_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Share Of U S Development And Commercialization Cost Under Collaboration Arrangement

+ References

No definition available.

+ Details

Name:	mdvn_ShareOfUSDevelopmentAndCommercializationCostUnderCollaborationArrangement
Namespace Prefix:	mdvn_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Share Percentage Of Development And Commercialization Cost Under Current Collaboration

+ References

No definition available.

+ Details

Name:	mdvn_SharePercentageOfDevelopmentAndCommercializationCostUnderCurrentCollaboration
Namespace Prefix:	mdvn_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Share Percentage Of Development And Commercialization Cost Under Former Collaboration

+ References

No definition available.

+ Details

Name:	mdvn_SharePercentageOfDevelopmentAndCommercializationCostUnderFormerCollaboration
Namespace Prefix:	mdvn_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of deferred revenue recognized for transactions arising during the current reporting period. Deferred revenue is a liability as of the balance sheet date related to a revenue producing activity for which revenue has not yet been recognized. Generally, an Entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.A.4(a).Q1)

-URI http://asc.fasb.org/extlink&oid=6600647&loc=d3e214044-122780

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section A

+ Details

Name:	us-gaap_DeferredRevenueAdditions
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Details

Name:	us-gaap_DeferredRevenueArrangementLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

Collaboration Agreements - Additional Information (Detail) (USD $) In Millions, unless otherwise specified	3 Months Ended
	Mar. 31, 2013	Mar. 31, 2013 Astellas [Member]	Mar. 31, 2013 Astellas [Member] Collaborative Agreement [Member] Minimum [Member]	Mar. 31, 2013 Astellas [Member] Collaborative Agreement [Member] Maximum [Member]	Mar. 31, 2013 Pfizer [Member]	Mar. 31, 2013 Up-front cash payment arrangement [Member] Astellas [Member]	Dec. 31, 2009 Up-front cash payment arrangement [Member] Astellas [Member]	Dec. 31, 2008 Up-front cash payment arrangement [Member] Pfizer [Member]	Mar. 31, 2013 Development milestone payments [Member]	Mar. 31, 2013 Development milestone payments [Member] Astellas [Member]	Mar. 31, 2013 Sales milestone payments [Member]	Mar. 31, 2013 Sales milestone payments [Member] Astellas [Member]	Dec. 31, 2008 Development cost-sharing payments [Member] Pfizer [Member] Collaborative Agreement [Member]	Mar. 31, 2013 Development cost-sharing payments [Member] Astellas [Member] Collaborative Agreement [Member]	Dec. 31, 2008 Commercial cost sharing-payments [Member] Pfizer [Member] Collaborative Agreement [Member]	Mar. 31, 2013 Commercial cost sharing-payments [Member] Astellas [Member] Collaborative Agreement [Member]
Deferred Revenue Arrangement [Line Items]
Co-promotion of sales and medical affairs percentage	50.00%
Royalty received on ex-U.S. sales per collaboration arrangement			10.00%	20.00%
Non-refundable up-front cash payment							$ 110.0	$ 225.0
Eligible to receive milestone payments										335.0
Maximum eligible future sales milestone payments under collaboration arrangement												320.0
Deferred revenue additions related to development milestones										58.0
Remaining development milestone payments the Company is eligible to receive									277.0		320.0
Percentage share of development milestone payments										10.00%
Percentage of sales milestone payments	10.00%
Share percentage of developing and commercializing dimebon													60.00%		40.00%
Share percentage of developing and commercializing														50.00%		50.00%
Share percentage of developing and commercializing dimebon														33.33%		66.67%
Collaboration revenue percentage compared to U.S. XTANDI net sales	50.00%
Aggregate milestone payments received		$ 168.0			$ 225.0	$ 110.0				$ 58.0